新型口服抗菌药SMT-571对多重耐药和广泛耐药淋球菌的体外活性
该研究通过琼脂稀释法和Etest法,检测了新型小分子抗菌药SMT-571对228株临床淋球菌分离株和34株国际参考菌株(共262株,含多重耐药和广泛耐药菌株)的体外活性。结果显示SMT-571对全部菌株均有强效活性,MIC范围为0.064-0.125 mg/L,MIC50、MIC90和众数MIC均为0.125 mg/L,且与头孢曲松、阿奇霉素等对照药物无交叉耐药。SMT-571有望成为口服治疗淋病的有效选择,但需随机对照临床试验进一步验证。
要点
- SMT-571对全部262株淋球菌(含MDR和XDR)均有强效体外活性。
- MIC50、MIC90和众数MIC均为0.125 mg/L,MIC范围0.064-0.125 mg/L。
- SMT-571与现有淋球菌治疗药物无交叉耐药或MIC相关性。
核心结论
- SMT-571对所有 tested 淋球菌分离株均有强效体外活性,且与既往和当前使用的抗菌药物无交叉耐药。
- 结合其口服生物利用度高的临床前数据,SMT-571可能是淋病口服治疗的有效选择。
研究设计与样本
- 研究检测了228株临床淋球菌分离株和34株国际淋球菌参考菌株,共262株,包括大量MDR和XDR分离株。
- SMT-571的MIC采用琼脂稀释法测定;头孢曲松、头孢克肟、阿奇霉素、环丙沙星、氨苄西林、大观霉素和四环素的MIC采用Etest测定。
主要发现
- SMT-571对所有 tested 淋球菌分离株(n=262)均显示强效体外活性。
- SMT-571的MIC范围为0.064至0.125 mg/L,MIC50、MIC90和众数MIC均为0.125 mg/L。
- 未观察到SMT-571与对照药物之间的交叉耐药或MIC相关性。
临床怎么用
- SMT-571可作为淋病口服治疗的潜在候选药物,尤其针对MDR和XDR淋球菌感染。
- 需开展随机对照临床试验,评估SMT-571治疗淋病的疗效、药代动力学/药效学、毒性及安全性,并纳入泌尿生殖道和泌尿生殖道外(直肠和咽部)样本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lack of effective treatment of gonorrhoea due to increasing antimicrobial resistance in Neisseria gonorrhoeae is a serious threat to the management and control of the infection. Novel antimicrobials are required to prevent the infection becoming untreatable. OBJECTIVES: Herein, we investigated the in vitro activity of a novel small-molecule antimicrobial with a new mechanism of action, SMT-571, against a large collection of clinical N. gonorrhoeae isolates (n = 228) and international gonococcal reference strains (n = 34), including numerous MDR and XDR gonococcal isolates. METHODS: MICs of SMT-571 were determined by agar dilution and MICs of ceftriaxone, cefixime, azithromycin, ciprofloxacin, ampicillin, spectinomycin and tetracycline were determined by Etest. RESULTS: SMT-571 showed potent in vitro activity against all the tested N. gonorrhoeae isolates (n = 262). The MICs ranged from 0.064 to 0.125 mg/L and the MIC50, MIC90 and modal MIC were all 0.125 mg/L. No cross-resistance or correlation between the MICs of SMT-571 and comparator agents was seen. CONCLUSIONS: SMT-571 demonstrated potent in vitro activity against all tested gonococcal isolates and no cross-resistance to previously and currently used antimicrobials was seen. With its promising supplementary in vitro and in vivo preclinical data, including high levels of oral bioavailability, SMT-571 could be an effective option for the oral treatment of gonorrhoea. Randomized controlled clinical trials for gonorrhoea that examine the treatment efficacy, pharmacokinetics/pharmacodynamics, toxicity and safety of SMT-571, and include urogenital and extragenital (rectal and pharyngeal) samples, are crucial.
引用
- Jacobsson S, Mason C, Khan N, et al. In vitro activity of the novel oral antimicrobial SMT-571, with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae: future treatment option for gonorrhoea? J Antimicrob Chemother. 2019. PMID: 30778550. doi:10.1093/jac/dkz060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。